See more : Grupo Comercial Chedraui, S.A.B. de C.V. (CHDRAUIB.MX) Income Statement Analysis – Financial Results
Complete financial analysis of Quotient Limited (QTNT) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Quotient Limited, a leading company in the Medical – Devices industry within the Healthcare sector.
- The Charles Schwab Corporation (SCHW) Income Statement Analysis – Financial Results
- Athena Consumer Acquisition Corp. (ACAQ) Income Statement Analysis – Financial Results
- Gibb River Diamonds Limited (GIB.AX) Income Statement Analysis – Financial Results
- Crixus BH3 Acquisition Company (BHACU) Income Statement Analysis – Financial Results
- Continental Securities Limited (CSL.BO) Income Statement Analysis – Financial Results
Quotient Limited (QTNT)
About Quotient Limited
Quotient Limited, a commercial-stage diagnostics company, develops, manufactures, commercializes, and sells products for the global transfusion diagnostics market in the United States, France, Japan, and internationally. The company is developing MosaiQ, a proprietary technology platform, which provides tests for immunohematology, serological disease screening, and molecular disease screening. Its conventional reagent products for blood grouping include antisera products that are used to identify blood group antigens; reagent red blood cells, which enable the identification of blood group antibodies; whole blood control products for use as daily quality assurance tests; and ancillary products that are used to support blood grouping. The company also offers MosaiQ SDS Microarray that is designed as a serological disease screening microarray comprised assays to detect cytomegalovirus and Syphilis; MosaiQ MDS Microarray that is designed as a molecular disease screening microarray test for donor red cells or source plasma; MosaiQ IH Microarray as a blood grouping microarray; MosaiQ Autoimmune Microarray; MosaiQ COVID-19; and MosaiQ IH3 Microarray. It sells its products to hospitals, donor collection agencies, independent testing laboratories, original equipment manufacturers, and blood banking operation and other diagnostics companies. Quotient Limited was founded in 2007 and is headquartered in Eysins, Switzerland.
| Metric | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 38.51M | 43.38M | 32.66M | 29.13M | 24.73M | 22.23M | 18.52M | 18.41M | 19.76M | 14.37M | 12.22M | 10.03M |
| Cost of Revenue | 23.57M | 20.07M | 17.80M | 17.23M | 10.47M | 10.84M | 9.66M | 9.76M | 8.41M | 7.17M | 6.75M | 5.63M |
| Gross Profit | 14.95M | 23.31M | 14.86M | 11.90M | 14.26M | 11.38M | 8.86M | 8.65M | 11.35M | 7.20M | 5.47M | 4.41M |
| Gross Profit Ratio | 38.80% | 53.72% | 45.49% | 40.86% | 57.66% | 51.21% | 47.86% | 46.96% | 57.45% | 50.11% | 44.77% | 43.91% |
| Research & Development | 58.69M | 54.17M | 53.74M | 50.68M | 51.20M | 57.06M | 28.78M | 19.22M | 8.07M | 2.62M | 1.75M | 1.70M |
| General & Administrative | 49.06M | 41.80M | 31.95M | 31.55M | 25.70M | 22.72M | 26.10M | 16.39M | 9.47M | 6.82M | 6.01M | 5.35M |
| Selling & Marketing | 11.02M | 9.85M | 9.85M | 8.64M | 7.35M | 5.66M | 3.07M | 2.75M | 2.71M | 2.25M | 1.67M | 1.46M |
| SG&A | 60.08M | 51.65M | 41.80M | 40.18M | 33.05M | 28.38M | 29.17M | 19.14M | 12.18M | 9.08M | 7.69M | 6.80M |
| Other Expenses | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Expenses | 118.77M | 105.81M | 95.55M | 90.86M | 84.25M | 85.44M | 57.95M | 38.36M | 20.24M | 11.69M | 9.43M | 8.51M |
| Cost & Expenses | 142.34M | 125.89M | 113.35M | 108.09M | 94.72M | 96.29M | 67.61M | 48.12M | 28.65M | 18.86M | 16.18M | 14.13M |
| Interest Income | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 57.00K | 87.00K | 0.00 |
| Interest Expense | 31.95M | 25.92M | 23.86M | 20.02M | 15.37M | 9.90M | 4.15M | 2.32M | 1.08M | 291.00K | 427.00K | 312.00K |
| Depreciation & Amortization | 7.42M | 8.62M | 12.28M | 12.77M | 10.41M | 9.46M | 2.95M | 1.68M | 622.00K | 691.00K | 989.00K | 980.00K |
| EBITDA | -84.80M | -72.01M | -65.98M | -72.56M | -57.22M | -65.71M | -26.78M | -55.07M | -8.47M | -3.73M | -3.06M | -3.33M |
| EBITDA Ratio | -220.17% | -165.99% | -202.04% | -249.05% | -231.35% | -295.61% | -144.60% | -299.15% | -42.86% | -25.97% | -25.02% | -33.18% |
| Operating Income | -92.22M | -82.51M | -80.69M | -78.96M | -69.99M | -74.06M | -49.09M | -29.71M | -8.89M | -4.49M | -3.96M | -4.10M |
| Operating Income Ratio | -239.43% | -190.20% | -247.09% | -271.01% | -282.99% | -333.19% | -265.03% | -161.42% | -45.01% | -31.25% | -32.44% | -40.85% |
| Total Other Income/Expenses | -31.95M | -24.04M | -21.42M | -26.39M | -13.00M | -11.01M | 15.21M | -29.35M | -1.27M | -223.00K | -509.00K | -522.00K |
| Income Before Tax | -124.17M | -106.54M | -102.11M | -105.34M | -82.99M | -85.07M | -33.88M | -59.06M | -10.17M | -4.71M | -4.47M | -4.62M |
| Income Before Tax Ratio | -322.40% | -245.61% | -312.69% | -361.58% | -335.55% | -382.73% | -182.91% | -320.83% | -51.46% | -32.80% | -36.61% | -46.05% |
| Income Tax Expense | 961.00K | 1.93M | 661.00K | 44.00K | -649.00K | -1.11M | 19.36M | -27.03M | -197.00K | 68.00K | -82.00K | -210.00K |
| Net Income | -125.13M | -108.47M | -102.77M | -105.39M | -82.34M | -85.07M | -33.88M | -59.06M | -10.17M | -4.71M | -4.47M | -4.62M |
| Net Income Ratio | -324.89% | -250.05% | -314.71% | -361.73% | -332.92% | -382.73% | -182.91% | -320.83% | -51.46% | -32.80% | -36.61% | -46.05% |
| EPS | -49.11 | -47.35 | -57.41 | -76.82 | -80.65 | -120.90 | -69.29 | -159.91 | -22.13 | -13.12 | -12.45 | -12.86 |
| EPS Diluted | -49.11 | -47.35 | -57.41 | -76.82 | -80.65 | -120.90 | -69.29 | -159.91 | -22.13 | -13.12 | -12.45 | -12.86 |
| Weighted Avg Shares Out | 2.55M | 2.29M | 1.79M | 1.37M | 1.02M | 703.64K | 488.95K | 369.34K | 459.41K | 359.41K | 359.41K | 359.41K |
| Weighted Avg Shares Out (Dil) | 2.55M | 2.29M | 1.79M | 1.37M | 1.02M | 703.64K | 488.95K | 369.34K | 459.41K | 359.41K | 359.41K | 359.41K |
Why Quotient Stock Is Soaring Today
Quotient Limited to Report Fourth Quarter and Full Year 2022 Financial Results and Host Conference Call on June 22nd
Quotient Limited (QTNT) CEO Manuel Mendez on Q3 2022 Results - Earnings Call Transcript
Quotient (QTNT) Reports Q3 Loss, Tops Revenue Estimates
Nuformix hails progress partner is making with reformulated anti-sickness drug
Quotient Limited to Report Third Quarter Fiscal Year 2022 Financial Results and Host Conference Call
Quotient (QTNT) May Report Negative Earnings: Know the Trend Ahead of Q3 Release
Quotient (QTNT) Upgraded to Buy: Here's What You Should Know
Rising P/E: An Overlooked Trick to Land on 5 Winning Stocks
Is the Options Market Predicting a Spike in Quotient Limited (QTNT) Stock?
Source: https://incomestatements.info
Category: Stock Reports